Colorectal cancer (CRC) is the fourth leading cause of cancer mortality worldwide. Genome-wide association studies (GWAS) identified more than 50 CRC loci. However, most of the previous studies were conducted in European population, and host genetic factors among Japanese population are largely remained to be identified. To identify novel loci in the Japanese population, here, we performed a large-scale GWAS using 6692 cases and 27 178 controls followed by a replication analysis using more than 11 000 case-control samples. We found the significant association of 10 loci (P < 5 × 10 -8 ), including 2 novel loci on 16q24.1 (IRF8-FOXF1, rs847208, P = 3.15 × 10 -9 and odds ratio = 1.107 with 95% confidence interval (CI) of 1.071-1.145) and 20q13.12 (TOX2, rs6065668, P = 4.47 × 10 -11 and odds ratio = 0.897 with 95% CI of 0.868-0.926). Moreover, 35 previously reported single nucleotide polymorphisms (SNPs) in 24 regions were validated in the Japanese population (P < 0.05) with the same risk allele as in the previous studies. SNP rs6065668 was significantly associated with TOX2 expression in the C. Tanikawa et al. | 653 
Introduction
Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer-related death worldwide (1) . There are 1.7 million new CRC cases and 832 000 deaths per year (2) . A westernized lifestyle that includes risk factors such as obesity, sedentary behavior and a high-meat, high-fat and fiberdeficient diet is linked to an increased CRC risk (3, 4) . In addition, nearly 15% of all patients with CRC have a positive family history of the disease (5, 6) , and an approximately 2-fold increased risk of CRC is observed among patients who have a first-degree relative with CRC in the European and Japanese populations (7, 8) . Inherited susceptibility is thought to account for 35% of all CRC cases (9) , and high-risk germline mutations in the APC (adenomatosis polyposis coli) gene, DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2), MUTYH, SMAD4, BMPR1A and LKB1 account for less than 6% of all cases (10) . Therefore, the remaining heritable CRC risk (approximately 30%) is explained by the combination of common variants with modest effects. More than 20 genome-wide association studies (GWAS) of CRC have successfully identified common SNPs (single nucleotide polymorphisms) associated with CRC risk (11) (12) (13) at 8q24 (14, 15) , 18q21.1 (SMAD7), 11q23 (C11orf93) (16) , 14q22.2 (BMP4), 16q22.1 (CDH1), 19q13.1 (BABAM1), 20p12.3 (FGFR3P3-CASC20) (17) , 15q13.3 (GREM1) (18) , 10p14 (GATA3), 8q23.3 (EIF3H) (19) , 1q41 (DUSP10), 3q26.2 (MYNN), 12q13.13 (KRT8), 20q13.33 (LAMA5) (20) , 6q26-q27 (12), 5q31.1 (C5orf66), 12p13.32 (CCND2) (21) , 5q31.1 (C5orf66), 20p12.3 (FGFR3P3) (22) , 6p21, 11q13.4 (POLD3), Xp22.2 (SHROOM2) (23) (27) and 10q25 (TCF7L2) (28) . Because most of these studies were conducted in European or Chinese population, further analyses of samples with various ethnic backgrounds are necessary to elucidate the genes susceptible to CRC. Here, we performed GWAS using more than 40 000 Japanese case-control sample sets and identified two novel loci at 16q24.1 and 20q13.12.
Material and methods

Sample
The characteristics of each cohort are shown in Supplementary Table 1 , available at Carcinogenesis Online. DNA samples of 7090 CRC patients in the screening and 3713 CRC patients and 7333 noncancer controls in the replication analysis were obtained from BioBank Japan (29, 30) . The 33 887 noncancer controls were from three population-based cohorts, including the JPHC (Japan Public Health Center)-based prospective study (31) , the J-MICC (Japan Multi-Institutional Collaborative Cohort) study (32) and ToMMo (Tohoku Medical Megabank Organization) (33, 34) . After initial quality check, 6692 cases and 27 178 controls were used for screening. A total of 6171 gastric cancer cases and 1225 esophageal cancer cases were obtained from BioBank Japan. Genomic DNA samples were extracted from peripheral blood leukocytes and normal tissues using a standard method. All participants provided written, informed consent and the ethical committees at each institute approved the project.
SNP genotyping and imputation analysis
A total of 7090 CRC cases from BioBank Japan and 33 887 healthy controls from J-MICC, JPHC and ToMMo were genotyped by Illumina OmniExpressExome or the OmniExpress + HumanExome BeadChip. Among them, we excluded 25 cases and 1861 controls because of gender mismatch. Closely related samples (365 cases and 3129 controls), which were estimated using identity by state, were excluded by visual inspection. In addition, we excluded 8 cases and 27 controls those were determined as outliers from the East Asian cluster by principal component analysis (35) . In addition, 1692 controls with past history of any cancers were excluded from analysis. Finally, a total of 398 cases (5.6%) and 6709 controls (19.8%) were excluded by initial QC. Finally, 6692 cases and 27
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178 controls were used for this study (Supplementary Table 1 , available at Carcinogenesis Online). We excluded SNPs that met the following criteria: MAF < 0.01; Hardy-Weinberg equilibrium P < 1 × 10 -6 or call rate < 0.99. Finally, we selected 509 872 SNPs from 951 117 SNPs for further imputation analysis. Imputation of the ungenotyped SNPs was conducted by MaCH (36) and minimac (37) using the data from the JPT/CHS/CHD subjects and using the 1000 Genome Project Phase 1 (release 16 March 2012) as a reference. We exclude SNP with a large allele frequency difference between the reference panel and the GWAS (>0.16) as described previously (38) . We also excluded SNPs with low imputation quality score (Rsq < 0.3) and insertion/ deletion polymorphisms. Among 539 SNPs within 32 genomic regions for which P < 1 × 10 -6 in the GWAS stage, we selected 1 or 2 SNPs from each region according to the following strategies: 1) lead SNP (the lowest P-value) within each region. 2) If the quality of genotyping by Invader assay (Third Wave Technologies) is not good (call rate <0.95), we selected another SNP within the region instead of lead SNP. 3) If there are SNPs that are low LD with lead SNP (r 2 < 0.2) and low P-value in GWAS stage (P < 1 × 10 -6 ), we selected the second SNP within this region. Finally, we selected 35 SNPs within 32 regions for the replication analysis. In the replication analysis, we genotyped 35 SNPs in 3713 CRC cases and 7333 controls using the multiplex PCR-based invader assay (Third Wave Technologies).
Statistical analysis
We excluded samples from the analysis that involved closely related samples, gender-mismatched samples and samples from subjects whose ancestries were estimated to be distinct from East Asian population using a principal component analysis. Then, we applied the SNP quality control as follows: a call rate ≥0.99 in the case and control samples, a minor allele frequency of ≥0.01 and a P-value of Hardy-Weinberg equilibrium in the control group ≥1 × 10 -6 . Consequently, 509 872 SNPs on autosomal chromosomes passed the quality control filters.
The association of SNPs with CRC risk was investigated using logistic regression analysis using PC1 and PC2 as covariates. To characterize the population structure in the GWAS cohort, we performed a principal component analysis (35) . In the GWAS, the genetic inflation factor λ was derived from P-values obtained by the Cochran-Armitage trend test for all the tested SNPs. The quantile-quantile plot was drawn using the R program. λ 1000 was calculated using the following formula (39) Odds ratios were calculated using the noneffect alleles as references, unless stated otherwise. The results of the combined analyses of the GWAS and the replication stage were verified by the Mantel-Haenszel method. Heterogeneity across the two stages was examined using P-link (40) . We considered P = 5 × 10 -8 (GWAS and meta-analysis) as the significance threshold after Bonferroni correction for multiple testing.
Data availability
Individual phenotype data, genotyping data, imputation data and summary statistics that support the findings of this study can be found at NDBC with the primary accession code hum0014 (http://humandbs.biosciencedbc.jp/), after the acceptance of this article. Some access restrictions are applied to the individual data for approved reasons.
Result
Genome-wide association study of CRC
The study design and characteristics of each cohort are shown in the Supplementary Figure 1 and Supplementary Table 1 , available at Carcinogenesis Online. DNA samples of 6692 CRC patients and 27 178 noncancer controls were genotyped by using Illumina OmniExpressExome or the OmniExpress + HumanExome Beadchip. After performing a standard quality control procedure, we conducted genome-wide imputation and obtained the genotyping results of 6 774 630 SNPs. The genomic inflation factor λ was calculated to be 1.248 and 1.023 (λ 1000 ) (39) Figure 2 . Forest plots for risk variants in the two novel CRC risk loci. Plots show the association estimates (odds ratios) and 95% CIs for the screening stage, and the replication studies presented as bars. The association estimate and CI for the meta-analysis combining screening and the replication results are shown as a diamond. The size of the square box is proportional to the number of cases and controls in each study site. Heterogeneity across the two stages was examined using the Cochrane's Q test.
(Supplementary Figure 2 , available at Carcinogenesis Online). We selected 35 SNPs in 32 genomic regions with a suggestive association (P < 1.0 × 10 -6 ) for further replication analyses (Figure 1 and Supplementary Tables 2 and 3 , available at Carcinogenesis Online).
Thirty-five SNPs were successfully genotyped by the invader assay, using 3713 cases and 7333 noncancer controls from BioBank Japan (Supplementary Table 4 , available at Carcinogenesis Online). In addition to the eight previously reported loci, two novel loci showed a significant association with a P-value < 0.05 and the same risk allele as in the GWAS (P = 7.36 × 10 -3 and 6.92 × 10 -4 , respectively). A meta-analysis of the two studies using P-link indicated that the two novel regions on 16q24.1 and 20q13.12 showed a significant association without a significant heterogeneity {P-values of 3.15 × 10 -9 and 4.47 × 10 -11 with odds ratios of 1.107 [95% confidence interval (CI); 1.071-1.145] and 0.897 (95% CI; 0.868-0.926), respectively; Figure 2 , Table 1 Figure 3 , available at Carcinogenesis Online).
In our study, age and sex distribution were different between cases and controls. Therefore, we conducted logistic regression analysis using age and gender as well as PC1/PC2 as covariates at GWAS stage. As a result, both two SNPs (rs847208 and rs6065668) showed strong association with OR of 1.121 (1.071-1.172) and 0.903 (0.863-0.945; Supplementary Table 6 , available at Carcinogenesis Online). Although the impact of each SNP was slightly weakened in the logistic regression analysis, OR is almost similar with those in the GWAS (OR of 1.119 and 0.893). Thus, sex and age distribution did not strongly affect the results, and these two loci are considered as CRC loci.
Identification of 16q24.1 as novel CRC locus
Regional plots of the two novel and eight reported loci are shown in Figure 3 and Supplementary Figure 4 , available at Carcinogenesis Online. Two SNPs, rs847208 and rs1622718, on 16q24.1 showed a strong association (P = 4.61 × 10 -8 and 3.74 × 10 -7 , respectively) in the GWAS (Supplementary Table 7 , available at Carcinogenesis Online). These two SNPs are located in the intergenic region between IRF8 and FOXF1. To investigate the functional roles of these variations, we examined the association of two novel variations (rs847208 and rs1622718) with the expression of nearby genes by using the eQTL database from the GTEx portal website (http://www.gtexportal.org/home/) (41) . As a result, rs847208 and rs1622718 were not associated with the expression of any genes within a 500 kb region. The SNP rs16941835, near FOXL1 (approximately 440 kb away from rs847208), showed a strong association with CRC risk in the previous analysis (P = 5.06 × 10 -8 ) within a European population (42) , but this SNP did not clear the genome-wide significant threshold (P = 5 × 10 -8 ) (43) . The SNP rs16941835 is in weak linkage disequilibrium with rs847208 (r 2 = 0.051 and D′ = 0.636, Supplementary Table 8 , available at Carcinogenesis Online) and is also associated with CRC risk in our GWAS stage (P = 0.009 and OR = 0.935, Supplementary Table 9 , available at Carcinogenesis Online). Taken together, this locus is considered a novel CRC locus among both European and Asian populations.
Association of rs6065668 with TOX2 expression in colon
The SNP rs6065668 on 20q13.12 is located in the promoter region of the TOX2 gene. Twenty-one SNPs within a 6 kb region at the 5′ flanking region of the TOX2 gene (from −14089 to −8271) showed a strong association with a P-value of <5 × 10 -8 (Supplementary  Table 10 , available at Carcinogenesis Online). The eQTL analysis revealed that the T allele of rs6065668 was significantly associated with a higher TOX2 mRNA expression in more than 20 tissues, including the large intestine (Supplementary Figure 5A and B, available at Carcinogenesis Online). To examine the regulatory role of the genetic variations on TOX2 expression, we selected seven SNPs (rs6065673, rs11086902, rs11086903, rs11086904, rs13036809, rs6073251 and rs13043229) that were associated with CRC with P-values <1 × 10 -6 in the GWAS and that are located in the regulatory region of the TOX2 gene (H3K4Me1, H3K4Me3 or H3K27Ac positive in Encode database, Supplementary Figure 6 , available at Carcinogenesis Online). Among these SNPs, three SNPs, rs11086902, rs13036809 and rs6073251, were predicted to affect the binding of some transcription factors (Supplementary Figure 7A , available at Carcinogenesis Online). Because SNPs rs11086902, rs13036809 and rs6073251 are in absolute linkage disequilibrium with lead SNP rs6065668 (r 2 = 1), one or several of these SNPs may be the functional, affecting TOX2 expression and subsequently altering the CRC risk. Among them, the C allele of rs13036809 is associated with a higher expression of TOX2 mRNA (Supplementary Figure 7B , available at Carcinogenesis Online) and is predicted to have higher binding values to KLF5, which is associated with the development of tumors derived from intestinal stem cells (44) . Taken together, TOX2 is a putative causative gene in this region that might play an important role in colorectal carcinogenesis.
Role of 20q13.12 in digestive tract malignancies
To further investigate the role of these novel loci in other gastrointestinal malignancies, we analyzed these SNPs in esophageal cancer and gastric cancer. As a result, both SNPs showed a similar trend of association with esophageal cancer and gastric cancer (Supplementary Table 11 , available at Carcinogenesis Online). Specifically, rs6065668 on 20q13.12 exhibited a significant association with gastric cancer (P = 1.56 × 10 -3 and OR of 0.936 with 95% CI of 0.898-0.975). Taken together, our analyses indicate the role of these variations as common loci for gastrointestinal cancers.
Association of previously reported CRC loci in Japanese population
We also analyzed previously reported CRC loci in our screening dataset. We obtained the results of 56 SNPs in 39 regions and found that 35 SNPs in 24 regions showed a significant association (P < 0.05) with the same risk allele as in the previous studies (Table 2 ). In addition, 17 SNPs among the remaining 21 SNPs showed a trend of association with the same risk allele as 
Discussion
Here, we identified 16q24.1 and 20q13.12 as novel loci that were significantly associated with CRC in the Japanese population. Although more than 20 CRC GWAS are reported, most of these studies were conducted in European or Chinese population. Our group previously reported a GWAS of distal colon cancer (12) , but this is the first GWAS for CRC in a Japanese population. Because more than 10 000 Japanese cases and 34 000 controls were analyzed, this is one of the most comprehensive CRC studies among Asian population.
We found that the risk allele of SNP rs6065668 was associated with higher TOX2 expression. TOX2 is a transcription factor that shares a high mobility group DNA-binding domain with the other TOX members. TOX2 directly regulates T-BET expression during human NK cell development (45) . In addition, TOX2 is suppressed in breast and lung cancer tissues by DNA hypermethylation (46) . However, the role of TOX2 in gastrointestinal malignancy is not reported to date. The rat ortholog GCX-1 shows exclusive expression of TOX2 in reproductive tissues, suggesting a specific role in follicular development (47) . Considering the potential role of KLF5 in tumor development from intestinal stem cells (44) and the allele-specific binding to the genomic region, including rs13036809, our findings suggest that higher TOX2 expression might be associated with the stem cell-like properties of the intestinal epithelial cells and, subsequently, increase the risk of CRC development.
Locus 16q24.1, including SNP rs847208, is associated with various diseases, such as chronic lymphocytic leukemia, systemic lupus erythematosus, inflammatory bowel disease and Barrett's esophagus. FENDRR that is located close to rs847208 is a noncoding RNA which binds PRC2 and is involved in the epigenetic regulation. Decreased expression of FENDRR is also associated with poor prognosis of gastric cancer (48) . Therefore, FENDRR might play some role in colorectal carcinogenesis. FOXF1, a forkhead family transcription factor, acts in the Hedgehog signaling pathway. A FOXF1 mutation causes malrotation and congenital short bowel and duodenal stenosis. Thus, FOXF1 plays an important role in the development of the gastrointestinal tract. The region around rs847208 contains multiple binding sites for various transcription factors, such as FOXP2, which is known to control FOXF1 expression. Deletion of about 75 kb region including rs847208 is associated with severe respiratory disease that is also caused by FOXF1 mutation (49) . Thus, genetic variations within this locus would be related to the transcriptional regulation of FOXF1 and, subsequently, increase CRC risk.
In this study, we used an old reference panel (Phase 1) for imputation analysis, while Phase 3 is currently available that may yield better results. In addition, insertion/deletion polymorphisms were excluded in this study. Therefore, germline genetic variants of possible importance might be missed in this study. Moreover, two novel loci were not analyzed in a different ethnic group. Therefore, further analysis using different imputation panel and sample set would elucidate the impact of genetic variations among Japanese and other populations.
In summary, we identified two novel loci in our study. In addition to the 2 novel loci, 24 known loci were associated with CRC risk in a Japanese population. CRC is still increasing in Japan due to a westernized lifestyle. Our findings contribute to the 
